• 10 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Onosma L. as a source of anticancer agents: phytochemistry to mechanistic insight
    Onosma (O.) is a genus of perennial flowering plants in the family Boraginaceae with approximately 250 species widely dispersed in temperate, tropical, and subtropical areas. It is traditionally use [...] Read more.
    Ajay Kumar ... Satwinderjeet Kaur
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:719–733
    DOI: https://doi.org/10.37349/etat.2022.00109
    This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
    View:1203
    Download:51
    Open Access
    Review
    The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors
    Prostate cancer (PCa) accounts as the most common non-cutaneous disease affecting males, and as the first cancer, for incidence, in male. With the introduction of the concept of immunoscore, PCa has [...] Read more.
    Maria Teresa Palano ... Lorenzo Mortara
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:694–718
    DOI: https://doi.org/10.37349/etat.2022.00108
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1537
    Download:58
    Times Cited: 0
    Open Access
    Review
    Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers
    In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant. Of the ways of patching up such deficit [...] Read more.
    Shiu Ying Tsao
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:676–693
    DOI: https://doi.org/10.37349/etat.2022.00107
    This article belongs to the special issue Theranostic Frontiers in Neuro-oncology
    View:1369
    Download:22
    Open Access
    Review
    Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies
    Steroid use is a widely accepted practice for both the treatment and prevention of tumor-induced edema, but there are many unknowns regarding their current clinical utility with modern anti-tumor th [...] Read more.
    Matthew Goldman ... Stephan Quintin
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:659–675
    DOI: https://doi.org/10.37349/etat.2022.00106
    View:1098
    Download:27
    Times Cited: 0
    Open Access
    Review
    Potential role of resveratrol and its nano-formulation as anti-cancer agent
    The uncontrolled and metastatic nature of cancer makes it worse and more unpredictable. Hence, many therapy and medication are used to control and treat cancer. However, apart from this, many medica [...] Read more.
    Akshay Kumar ... Dilpreet Singh
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658
    DOI: https://doi.org/10.37349/etat.2022.00105
    This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
    Open Access
    Review
    Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
    Recently, technological advances in the detection and biological characterization of circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into clinical practice. Me [...] Read more.
    Yoshiharu Sato
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:630–642
    DOI: https://doi.org/10.37349/etat.2022.00104
    This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
    View:1523
    Download:25
    Open Access
    Review
    Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions
    Cancer-associated fibroblasts (CAFs) are highly heterogeneous players that shape the tumor microenvironment and influence tumor progression, metastasis formation, and response to conventional therap [...] Read more.
    Jerome Thiery
    Published: October 27, 2022 Explor Target Antitumor Ther. 2022;3:598–629
    DOI: https://doi.org/10.37349/etat.2022.00103
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1564
    Download:27
    Open Access
    Original Article
    Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
    Aim: Diagnostic laboratories are progressively introducing next-generation sequencing (NGS) technologies in the routine workflow to meet the increasing clinical need for comprehensive molecular c [...] Read more.
    Iolanda Capone ... Giancarlo Pruneri
    Published: October 27, 2022 Explor Target Antitumor Ther. 2022;3:582–597
    DOI: https://doi.org/10.37349/etat.2022.00102
    This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment
    Open Access
    Commentary
    A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
    Solute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of t [...] Read more.
    Daniela Criscuolo ... Angela Celetti
    Published: October 25, 2022 Explor Target Antitumor Ther. 2022;3:570–581
    DOI: https://doi.org/10.37349/etat.2022.00101
    View:1311
    Download:35
    Open Access
    Original Article
    N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
    Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to  [...] Read more.
    Feng Yuan ... Chiyuan Ma
    Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569
    DOI: https://doi.org/10.37349/etat.2022.00100
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:1428
    Download:40